5.5. Cholesteryl ester transfer protein

5.5.1. Activity in different sexes and different types of hypercholesterolemia

CETP activity was higher in females (201 (53) nmol/h/l) than in males (162 (45) nmol/h/l) with p=0.03, but no differences were detected between the sexes during colestipol or lovastatin treatment. The CETP activities or changes during the drug treatment were similar in non-FH and FH patients and in patients with type II a and II b hypercholesterolemia.

5.5.2. Effect of apo E phenotypes on cholesteryl ester transfer protein activity and drug response

The CETP activity was 183 (59) nmol/h/ml in the apo E 2/3 and 3/3 patients and 179 (43) nmol/h/ml in the patients with the E4 allele. Colestipol reduced plasma CETP activity by 19.5% in the patients with apo E 2/3 or 3/3, and by 13.3% (p=0.41) in the patients with apo E 3/4 or 4/4, the corresponding reductions for lovastatin being 19.4% and 20.0 % (p=0.99). The best correlations between the CETP basal activity and the lipids were observed with LDL and total cholesterol after lovastatin treatment in the patients with apo E 2/3 or 3/3 (Table 5-6). The CETP change correlated well with the HDL cholesterol change during colestipol, but not lovastatin treatment in both the patients with the apo E 4 allele and those without it (Figure 5-3).

Table 5-6. Pearson correlation of lipids and their changes with the cholesteryl ester transfer protein basal activity according to apo E phenotype

 Apo E 2/3 and 3/3Apo E 4/3 and 4/4
Total cholesterol0.52 p=0.010.13 p=0.65
colestipol0.51 p=0.020.04 p=0.90
lovastatin0.65 p=0.0010.57 p=0.03
LDL cholesterol0.49 p=0.020.07 p=0.81
colestipol0.42 p=0.06-0.09 p=0.77
lovastatin0.65 p=0.00090.23 p=0.42
HDL cholesterol0.26 p=0.24 0.17 p=0.56
colestipol0.16 p=0.480.45 p=0.11
lovastatin0.36 p=0.100.32 p=0.27
Triglycerides-0.27 p=0.220.13 p=0.65
colestipol0.21 p=0.360.16 p=0.59
lovastatin-0.001 p=0.990.44 p=0.11

Figure 5-3. Correlation between the HDL cholesterol change and the cholesteryl ester transfer protein change during colestipol and lovastatin treatments in the apolipoprotein E phenotype groups.